Gateway To China: Developing Biologics For The Fastest-Growing Patient Population On Earth

Source: Thermo Fisher Scientific

China is the world’s second-largest pharmaceutical market, following the US, with a market share around 12% in global pharmaceutical sales in 2021.* With an aging population and the rise of new indications, this population makes an attractive market for any biopharmaceutical company. In this webinar, hear from Yan Fang Ma, general manager of Thermo Fisher’s site in Hangzhou, China, as she describes the opportunities and challenges multinational companies may face bringing biologics and sterile drug products to market in China and the how the right CDMO partner can provide trusted guidance along the way.

*Mikulic, M. (2021, November 15). Pharmaceutical value share by country worldwide 2021. Statista. Retrieved November 8, 2022, from https://www.statista.com/statistics/1246593/value-share-of-pharmaceutical-companies-worldwide-by-country/ 

Key takeaways:

  • What makes China an attractive market for biopharmaceutical companies?
  • What challenges do these companies face to develop and manufacture drugs in China?
  • What factors to keep in mind when choosing a CDMO partner to enter the China market
access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online